help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, C.
Right arrow Articles by Low, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, C.
Right arrow Articles by Low, B.
(American Journal of Pathology. 2006;168:1526-1530.)
© 2006 American Society for Investigative Pathology

Mortalin-Based Cytoplasmic Sequestration of p53 in a Nonmammalian Cancer Model

Charles Walker, Stefanie Böttger and Ben Low

From the Department of Zoology, Center for Marine Biology and Marine Biomedical Research Group, University of New Hampshire, Durham, New Hampshire

In nature the soft shell clam Mya arenaria develops a fatal neoplasm that shares molecular similarity with an unrelated group of human cancers. In leukemic clam hemocytes, wild-type p53 and mortalin proteins co-localize in the cytoplasm. A similar phenotype, characterized by cytoplasmic sequestration of wild-type p53 protein, has been observed in several human cancers (undifferentiated neuroblastoma, retinoblastoma, colorectal and hepatocellular carcinomas, and glioblastoma). In some of these cancers p53 is tethered in the cytoplasm by mortalin when the latter protein is overexpressed. Using co-immunoprecipitation we have demonstrated that mortalin and p53 proteins are complexed in the cytoplasm of leukemic clam hemocytes (and not in normal hemocytes). In addition, treatment of leukemic clam hemocytes with MKT-077, a cationic inhibitor of mortalin, disrupts the interaction of mortalin and p53 proteins, resulting in translocation of some p53 to the nucleus. Based on these data, we introduce leukemic clam hemocytes as novel and easily accessible, in vivo and in vitro models for human cancers displaying a similar mortalin-based phenotype. Treatment of these models with novel chemotherapeutics may help reveal the molecular mechanism(s) involved in inactivating p53 by this form of cytoplasmic sequestration.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. C. Ghosh, T. Dohi, B. H. Kang, and D. C. Altieri
Hsp60 Regulation of Tumor Cell Apoptosis
J. Biol. Chem., February 22, 2008; 283(8): 5188 - 5194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Bottger, E. Jerszyk, B. Low, and C. Walker
Genotoxic Stress-Induced Expression of p53 and Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53
Cancer Res., February 1, 2008; 68(3): 777 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
C. C. DEOCARIS, N. WIDODO, T. ISHII, S. C. KAUL, and R. WADHWA
Functional Significance of Minor Structural and Expression Changes in Stress Chaperone Mortalin
Ann. N.Y. Acad. Sci., November 1, 2007; 1119(1): 165 - 175.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. B. Gill, J. L. Kutok, and J. D. Fingeroth
Epstein-Barr Virus Thymidine Kinase Is a Centrosomal Resident Precisely Localized to the Periphery of Centrioles
J. Virol., June 15, 2007; 81(12): 6523 - 6535.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.